Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection

Autoimmun Rev. 2020 Jul;19(7):102563. doi: 10.1016/j.autrev.2020.102563. Epub 2020 May 5.

Authors

Louise Cunningham¹, Ian Kimber², David Arthur Basketter³, John Paul McFadden⁴

Affiliations

¹ St. John's Institute of Dermatology, Guy's and St Thomas' Hospital, London, UK. Electronic address: louise.cunningham@gstt.nhs.uk.
² Faculty of Biology, Medicine and Health, University of Manchester, UK.
³ DABMEB Consultancy Ltd, Sharnbrook, Bedfordshire, UK.
⁴ St. John's Institute of Dermatology, Guy's and St Thomas' Hospital, London, UK.

No abstract available

Keywords: COVID-19; Cytokine storm; IL-6; Interleukin-6; Macrophage activation syndrome; Natural killer cells; Perforin; SARS-CoV-2.

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
COVID-19
Coronavirus Infections
Cytokines
Humans
Interleukin-6*
Macrophage Activation Syndrome*
Pandemics
Pneumonia, Viral
SARS-CoV-2

Substances

Cytokines
Interleukin-6